Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 4 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Treatment Landscape for Cardiac Amyloidosis with Dr Sarah Cuddy
Author(s): Added: 6 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly… View more

Heart Failure
Transthyretin Cardiac Amyloidosis: A Right-atrial Variant
Author(s): Narra Lavanya , Abraham Oomman Added: 11 months ago

Imaging & Diagnostics

Heart Failure
Multimodality Imaging in Cardiac Amyloidosis with Dr Vasvi Singh
Author(s): Vasvi Singh Added: 6 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights… View more

Imaging & Diagnostics

Heart Failure
AHA 25: The AI-SCREEN-CA Study
Author(s): Nobuyuki Kagiyama Added: 4 months ago
AHA Scientific Sessions 2025 - Prof Nobuyuki Kagiyama (Juntendo University School of Medicine, Tokyo, JP) joins us to share findings from the AI-SCREEN-CA study investigating whether an artificial intelligence-based software for checking real-world echocardiography can improve the early and accurate detection of hidden cardiac amyloidosis.Findings showed that this AI software identified around 5%… View more

Imaging & Diagnostics

Heart Failure
AHA 24: Nexiguran Ziclumeran for ATTR-CM
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more

Heart Failure
William Moody
Job title: Consultant Cardiologist
Dr Will Moody is a consultant cardiologist with a specialist interest in cardiomyopathy and cardiac imaging. With accreditation in echocardiography, CMR and nuclear cardiac imaging, he is the cardiovascular imaging lead for University Hospitals Birmingham and the clinical lead for the Midlands Amyloidosis Service. Following entry onto the inaugural BCS Emerging Leaders Program, he has used this… View more
Carol J. Whelan
Research Area(s) / Expertise:

Heart Failure

Cardio-oncology

Cardiac Amyloidosis

 Job title: Consultant Cardiologist, National Amyloidosis Centre & Royal Free London Hospital, University College London, UK
In October 2009, the Royal Free London NHS Foundation Trust hired Dr. Carol Whelan as a consultant cardiologist with expertise in imaging, heart failure, and cardiac amyloidosis. As a result of her efforts at the National Amyloidosis Centre, she has been given the title of Honorary Associate Professor at UCL. In 2011, she was named the hospital's clinical lead for heart failure. In 2018, she was… View more
Julian Gillmore
Research Area(s) / Expertise:
Prof Julian Gillmore is Professor of Medicine at University College London, London, UK. His research interests include pathogenesis, diagnosis and treatment of amyloidosis. He was appointed Centre Head at UCL’s Centre for Amyloidosis & Acute Phase Proteins in 2019 and is clinical lead for ATTR amyloidosis at the UK National Amyloidosis Centre. He has published more than 250 peer-reviewed articles… View more
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Added: 4 weeks ago Source:  Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments… View more

Heart Failure